Horizon Discovery Group’s (HZD) “Hold” Rating Reaffirmed at Peel Hunt
Separately, Numis Securities restated a buy rating on shares of Horizon Discovery Group in a research report on Monday, September 17th.
HZD stock opened at GBX 172 ($2.25) on Monday. Horizon Discovery Group has a 12-month low of GBX 160 ($2.09) and a 12-month high of GBX 294 ($3.84).
Horizon Discovery Group plc, an integrated life science company, designs, manufactures, and applies gene editing and gene modulation to build cell models that harbour the genetics of human disease in the Americas, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company operates through Products, Services, and Leveraged Research and Development (R&D) segments.
Further Reading: How liquidity affects the bid-ask spread
Receive News & Ratings for Horizon Discovery Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Discovery Group and related companies with MarketBeat.com's FREE daily email newsletter.